Glaxosmithkline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
- Market Cap ₹ 32,977 Cr.
- Current Price ₹ 1,947
- High / Low ₹ 2,650 / 1,227
- Stock P/E 51.9
- Book Value ₹ 91.4
- Dividend Yield 1.64 %
- ROCE 36.0 %
- ROE 26.5 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 45.9%
- Company has been maintaining a healthy dividend payout of 107%
Cons
- Stock is trading at 21.3 times its book value
- The company has delivered a poor sales growth of 2.29% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2,376 | 2,626 | 2,546 | 3,288 | 2,826 | 2,903 | 2,872 | 3,129 | 3,225 | 2,920 | 3,218 | 3,216 | 3,279 | |
1,593 | 1,811 | 2,024 | 2,660 | 2,349 | 2,482 | 2,361 | 2,522 | 2,566 | 2,323 | 2,462 | 2,417 | 2,466 | |
Operating Profit | 782 | 815 | 522 | 627 | 477 | 421 | 511 | 606 | 658 | 598 | 756 | 799 | 812 |
OPM % | 33% | 31% | 20% | 19% | 17% | 14% | 18% | 19% | 20% | 20% | 23% | 25% | 25% |
-163 | 49 | 227 | 147 | 125 | 118 | 69 | 106 | -247 | 8 | 1,402 | 104 | -14 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 2 | 2 | 2 |
Depreciation | 20 | 18 | 20 | 25 | 25 | 27 | 38 | 49 | 83 | 79 | 68 | 66 | 69 |
Profit before tax | 599 | 847 | 729 | 749 | 576 | 511 | 542 | 664 | 322 | 524 | 2,087 | 835 | 728 |
Tax % | 28% | 32% | 31% | 37% | 35% | 34% | 35% | 36% | 66% | 32% | 19% | 27% | |
431 | 577 | 502 | 472 | 375 | 337 | 352 | 425 | 110 | 358 | 1,691 | 608 | 523 | |
EPS in Rs | 25.42 | 34.08 | 29.63 | 27.84 | 22.11 | 19.88 | 20.78 | 25.11 | 6.50 | 21.11 | 99.79 | 35.88 | 30.88 |
Dividend Payout % | 89% | 73% | 84% | 112% | 113% | 75% | 84% | 80% | 616% | 142% | 90% | 89% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | 2% |
3 Years: | 0% |
TTM: | 2% |
Compounded Profit Growth | |
---|---|
10 Years: | -1% |
5 Years: | 11% |
3 Years: | 44% |
TTM: | 47% |
Stock Price CAGR | |
---|---|
10 Years: | 4% |
5 Years: | 8% |
3 Years: | 11% |
1 Year: | 53% |
Return on Equity | |
---|---|
10 Years: | 27% |
5 Years: | 33% |
3 Years: | 46% |
Last Year: | 26% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 |
Reserves | 1,835 | 1,925 | 1,932 | 1,767 | 2,120 | 1,944 | 1,995 | 1,973 | 1,671 | 1,328 | 2,508 | 1,584 | 1,378 |
5 | 5 | 4 | 3 | 2 | 2 | 1 | 1 | 0 | 35 | 20 | 16 | 21 | |
1,086 | 1,075 | 1,129 | 1,382 | 864 | 991 | 1,884 | 1,766 | 1,291 | 1,565 | 1,925 | 1,559 | 1,697 | |
Total Liabilities | 3,011 | 3,090 | 3,150 | 3,236 | 3,071 | 3,021 | 3,965 | 3,909 | 3,132 | 3,097 | 4,623 | 3,328 | 3,266 |
99 | 89 | 100 | 123 | 204 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 318 | |
CWIP | 16 | 44 | 62 | 115 | 268 | 605 | 923 | 1,003 | 120 | 13 | 30 | 20 | 26 |
Investments | 160 | 103 | 58 | 48 | 54 | 48 | 48 | 25 | 24 | 24 | 390 | 543 | 538 |
2,736 | 2,854 | 2,930 | 2,950 | 2,545 | 2,110 | 2,670 | 2,450 | 2,229 | 2,672 | 3,871 | 2,435 | 2,383 | |
Total Assets | 3,011 | 3,090 | 3,150 | 3,236 | 3,071 | 3,021 | 3,965 | 3,909 | 3,132 | 3,097 | 4,623 | 3,328 | 3,266 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
322 | 294 | 267 | 341 | 138 | 232 | 475 | 411 | 491 | 595 | 820 | 488 | |
368 | -93 | 198 | 178 | 499 | 303 | -107 | -154 | -63 | 408 | -420 | 805 | |
-392 | -437 | -490 | -497 | -638 | -511 | -307 | -358 | -428 | -696 | -524 | -1,544 | |
Net Cash Flow | 298 | -236 | -25 | 22 | -1 | 25 | 61 | -102 | 0 | 307 | -124 | -251 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Dec 2011 | Dec 2012 | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 13 | 16 | 14 | 11 | 16 | 21 | 19 | 14 | 11 | 27 | 23 | 22 |
Inventory Days | 133 | 94 | 108 | 89 | 155 | 111 | 147 | 131 | 135 | 153 | 144 | 128 |
Days Payable | 80 | 78 | 88 | 74 | 96 | 72 | 148 | 109 | 99 | 131 | 156 | 122 |
Cash Conversion Cycle | 66 | 32 | 34 | 26 | 75 | 61 | 18 | 37 | 47 | 49 | 11 | 27 |
Working Capital Days | -51 | -43 | -46 | -49 | 25 | 6 | -91 | -72 | -35 | -36 | -95 | -58 |
ROCE % | 48% | 50% | 35% | 41% | 28% | 22% | 26% | 31% | 33% | 37% | 36% | 36% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
- Closure of Trading Window 2d
- Disclosure Under Clause 30 22 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 6 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from nse
Concalls
-
Feb 2024Transcript PPT
-
Mar 2023TranscriptPPT
-
Aug 2022Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
Leading Global Health care company[1] GlaxoSmithKline Pharmaceutical is a part of GlaxoSmithKline plc (GSK), a British multinational pharmaceutical company headquartered in London. GSK underwent a merger in 2000 of Glaxo Wellcome and SmithKline Beecham, and is the world’s sixth-largest pharmaceutical company.